Microbiome research has accelerated rapidly in recent years—and while these studies have provided valuable insights into human health, they have also made clear that microbiome research alone will not answer all of our fundamental questions […]
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides […]
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces that MB097 is now in pre-clinical development for treatment of patients not responding to anti-PD1 therapy. Clinical trials are due to begin in 2022. […]
Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it has entered into a research collaboration agreement with Roche for the discovery of a […]
Osel Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, announced that City of Hope, a world-renowned independent cancer and diabetes research and treatment center, presented […]
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the U.S. Food and Drug Administration (FDA) has indicated studies for SER-155 may proceed under an Investigational New Drug (IND) application. SER-155 is an […]
Basel, Switzerland and Hørsholm, Denmark, 31 May 2021 – Following GMP inspections by Swissmedic at Bacthera’s drug product facility in Basel, Switzerland, and by the Danish Medicines Agency at Bacthera’s drug substance facility in Hørsholm, […]
While the consequences of the COVID-19 pandemic have been devastating, it has also served as a key milestone on the road to understand the human microbiome and how it affects our health. Since the […]
Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company. […]
In October 2020, Chr. Hansen acquired Jennewein Biotechnologie GmbH including a strong patent portfolio relating to the production of Human Milk Oligosaccharides (HMOs) and several litigations related hereto. Before the acquisition in January 2020, Jennewein […]
A biomedical research company founded by a University of Alabama at Birmingham physician-scientist has received $3 million in seed funding. ResBiotic Inc. — spun off from UAB last year — will use the money to […]